10
Views
1
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Use of combined oral contraceptives for the management of heavy menstrual bleeding

&
Pages 485-489 | Published online: 10 Jan 2014
 

Abstract

Evaluation of: Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser I. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet. Gynecol. 117(4), 777–787 (2011).

Heavy menstrual bleeding (HMB) is one of the most common reasons for women to seek gynecological care. Surgical and medical treatments have been proposed, including hysterectomy, endometrial ablation, oral progestins, the levonorgestrel-releasing intrauterine system, mefenamic acid and combined oral contraceptives (COCs). Although COCs have been used extensively to control HMB, there is little evidence of their efficacy. A new COC containing estradiol valerate and dienogest was compared with placebo in a randomized clinical trial that included women with objectively confirmed HMB in whom blood loss was measured using the alkaline hematin method. Over 6 months of treatment, results showed that blood loss decreased significantly in COC users, both when compared with a placebo group and with a 90-day pretreatment period. This represents a new option for HMB treatment with the advantage of simultaneously providing contraception, a requirement for many women with HMB who wish to preserve their fertility. Despite these excellent results, the facts remain that HMB is a chronic medical condition and that this new therapy still requires long-term evaluation. Notwithstanding, this report is the first to describe the successful use of a COC to treat HMB, a challenging condition with limited options for conservative treatment.

Financial & competing interests disclosure

The authors declare that they have received financial support for research purposes from the World Health Organization, The Population Council, Bayer and MSD. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.